Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIB-IMRT and Concurrent Chemotherapy in Esophageal Carcinoma
NCT02429622Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2015
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial (4 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Disease-free survival at 3 years. Started Jan 2015; status: completed.
Beyond the preview
Go deeper on NCT02429622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429622.